DRRAX:NASDAQ
Dreyfus Global Real Return Fund Class A – DRRAX Fund Overview
| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|
| 14.63 | -0.04 (-0.27%) | 13.38 - 14.74 | 0.0 |
Market data as of 6:05PM 05/23/13. Quotes are delayed by at least 15 min.
Overview - DRRAX
The investment seeks total return.
The fund uses an actively-managed multi-asset strategy to produce absolute or real returns with less volatility than major equity markets over a complete market cycle, typically a period of five years. Rather than managing to track a benchmark index, it seeks to provide returns that are largely independent of market moves. The fund allocates its investments among global equities, bonds and cash, and, generally to a lesser extent, other asset classes, including real estate, commodities, currencies and alternative or non-traditional asset classes and strategies. It is non-diversified.
Growth of $10,000 (10 Years)
| Total Return | 5.87% |
|---|
| Yield (Trailing 12 Mo.) | 0.46% |
|---|
| Expense Ratio | 1.72% |
|---|
| Front Load | 5.75% |
|---|
| Deferred Load | None |
|---|
| Minimum Investment | $1,000 |
|---|
| Management Tenure | 3 Years |
|---|
| Fund Inception | 05/12/2010 |
|---|
Trailing Total Returns - DRRAX
as of 04/30/2013
| Timeframe | DRRAX | S&P 500 | World Allocation |
|---|
| 1 Month | 1.39% | 1.93% | 1.68% |
|---|
| 3 Month | 3.55% | 7.18% | 2.60% |
|---|
| Year-to-Date | 5.27% | 12.74% | 4.99% |
|---|
| 1 Year | 8.04% | 16.89% | 9.24% |
|---|
| 3 Year | -- | 12.80% | 7.61% |
|---|
| 5 Year | -- | 5.21% | 3.34% |
|---|
| 10 Year | -- | 7.88% | 8.36% |
|---|
| Since Inception | 5.87% | 10.38% | -- |
|---|
Sector Allocation - DRRAX
as of 04/30/2013
| Basic Materials | | 11.46% |
|---|
| Consumer Cyclical | | 2.29% |
|---|
| Financial Services | | 1.62% |
|---|
| Real Estate | | 0.00% |
|---|
| Consumer Defensive | | 15.23% |
|---|
| Healthcare | | 28.04% |
|---|
| Utilities | | 10.89% |
|---|
| Communication Services | | 16.28% |
|---|
| Energy | | 6.63% |
|---|
| Industrials | | 3.63% |
|---|
| Technology | | 3.94% |
|---|
Asset Allocation - DRRAX
as of 04/30/2013
| By Percent | Short | 0% | Long | Net |
|---|
| Stock | 0.00 | | | 17.34 | 17.34 |
|---|
| Bond | 0.00 | | | 2.86 | 2.86 |
|---|
| Other | 0.00 | | | 4.74 | 4.74 |
|---|
| Foreign Stock | 0.00 | | | 49.32 | 49.32 |
|---|
| Foreign Bond | 0.00 | | | 20.91 | 20.91 |
|---|
| Total | 0.00 | | | 95.17 | 95.17 |
|---|
| Cash | 77.54 | | | 82.37 | 4.83 |
|---|
| Total Net Assets | $85.97M |
|---|
| Total Stock Holdings | 46 |
|---|
| Total Bond Holdings | 56 |
|---|
Bond Credit Quality - DRRAX
as of 04/30/2013
| AAA | | 36.64% |
|---|
| AA | | 0.56% |
|---|
| A | | 1.30% |
|---|
| BBB | | 0.27% |
|---|
| BB | | 5.57% |
|---|
| B | | 5.39% |
|---|
| Below B | | 0.00% |
|---|
| Not Rated | | 50.27% |
|---|
Top Ten Holdings - DRRAX
as of 04/30/2013
| Company | YTD Return | % of Assets |
|---|
| DGL | -- | 3.77% |
|---|
| Bayer AG | -- | 3.59% |
|---|
| GlaxoSmithKline PLC | 20.09% | 3.55% |
|---|
| Australia(Cmnwlth) 5.5% | -- | 3.11% |
|---|
| Norway(Kingdom Of) 4.5% | -- | 3.06% |
|---|
| RAI | 15.52% | 2.80% |
|---|
| Novartis AG | 17.50% | 2.59% |
|---|
| MRK | 12.65% | 2.50% |
|---|
| Centrica PLC | 7.23% | 2.11% |
|---|
| Roche Holding AG | 23.65% | 2.11% |
|---|
Valuation & Growth - DRRAX
as of 04/30/2013
| Valuation | DRRAX | Category Range |
|---|
| Price/Earnings | 6.42 | |
|---|
| Price/Book | 2.35 | |
|---|
| Price/Sales | 1.34 | |
|---|
| Price/Cash Flow | 8.16 | |
|---|
| Dividend Yield | 3.52 | |
|---|
| LT Earnings | 9.82 | |
|---|
| Historical Earnings | 15.32 | |
|---|
| Sales Growth | -1.87 | |
|---|
| Cash-Flow Growth | -3.75 | |
|---|
| Book-Value Growth | -0.37 | |
|---|